Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV-1 virologic failure in the RESINA cohort: lessons from two decades of real-world data.

Infection - 1 Apr 2026

Gliga Smaranda, Böhm Micha, Lübke Nadine, Killer Alexander, Hüttig Falk, Haberl Lila, Timm Jörg, Müller Claudia, Heger Eva, Büch Joachim, Fätkenheuer Gerd, Lehmann Clara, Oette Mark, Hower Martin, Knechten Heribert, Schübel Niels, Esser Stefan, Schneeweiß Stephan, Qurishi Nazifa, Römer Katja, Rockstroh Jürgen K, Kaiser Rolf, Luedde Tom, Jensen Björn-Erik Ole

Abstract excerpt

PURPOSE: To quantify virologic failure (VF), identify predictors, characterize resistance patterns at failure, and evaluate time to resuppression in the RESINA cohort. METHODS: ART-naïve adults initiating ART in 2001-2024 were followed. VF was defined as at least one HIV-1 RNA > 200 copies/mL after suppression or ≥ 0.5-log₁₀ rebound. Participants were grouped by treatment era (2001-2007, 2008-2013, ≥ 2014),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Genotype

Share to HIV Infections

Share to Treatment Failure

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 41405678
DOI: 10.1007/s15010-025-02713-7
PMCID: PMC13021726

Genes

CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV-1 virologic failure in the RESINA cohort: lessons from two decades of real-world data.PMID 41405678Read ↗

Analysis of the Virological Failure Rates and Influencing Factors of ART Regimens Containing Integrase Inhibitors: A Retrospective Analysis from the Real World in ChongqingSemantic proximity Read ↗

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.Semantic proximity Read ↗

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens.Semantic proximity Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.Semantic proximity Read ↗

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.Semantic proximity Read ↗

Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.Semantic proximity Read ↗

Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study.Semantic proximity Read ↗

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudySemantic proximity Read ↗

Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes.Semantic proximity Read ↗

HIV Dolutegravir Resistance and Multiclass Failure in Mozambique: Findings from a Real-World CohortSemantic proximity Read ↗

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.